These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 17353237)

  • 1. Preclinical testing of candidate topical microbicides for anti-human immunodeficiency virus type 1 activity and tissue toxicity in a human cervical explant culture.
    Cummins JE; Guarner J; Flowers L; Guenthner PC; Bartlett J; Morken T; Grohskopf LA; Paxton L; Dezzutti CS
    Antimicrob Agents Chemother; 2007 May; 51(5):1770-9. PubMed ID: 17353237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A human colorectal explant culture to evaluate topical microbicides for the prevention of HIV infection.
    Abner SR; Guenthner PC; Guarner J; Hancock KA; Cummins JE; Fink A; Gilmore GT; Staley C; Ward A; Ali O; Binderow S; Cohen S; Grohskopf LA; Paxton L; Hart CE; Dezzutti CS
    J Infect Dis; 2005 Nov; 192(9):1545-56. PubMed ID: 16206069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of topical microbicides on infectious human immunodeficiency virus type 1 binding to epithelial cells.
    Roth S; Monsour M; Dowland A; Guenthner PC; Hancock K; Ou CY; Dezzutti CS
    Antimicrob Agents Chemother; 2007 Jun; 51(6):1972-8. PubMed ID: 17404008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro comparison of topical microbicides for prevention of human immunodeficiency virus type 1 transmission.
    Dezzutti CS; James VN; Ramos A; Sullivan ST; Siddig A; Bush TJ; Grohskopf LA; Paxton L; Subbarao S; Hart CE
    Antimicrob Agents Chemother; 2004 Oct; 48(10):3834-44. PubMed ID: 15388443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyanovirin-N potently inhibits human immunodeficiency virus type 1 infection in cellular and cervical explant models.
    Buffa V; Stieh D; Mamhood N; Hu Q; Fletcher P; Shattock RJ
    J Gen Virol; 2009 Jan; 90(Pt 1):234-43. PubMed ID: 19088294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical evaluation of lime juice as a topical microbicide candidate.
    Fletcher PS; Harman SJ; Boothe AR; Doncel GF; Shattock RJ
    Retrovirology; 2008 Jan; 5():3. PubMed ID: 18190686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a comprehensive human immunodeficiency virus type 1 screening algorithm for discovery and preclinical testing of topical microbicides.
    Lackman-Smith C; Osterling C; Luckenbaugh K; Mankowski M; Snyder B; Lewis G; Paull J; Profy A; Ptak RG; Buckheit RW; Watson KM; Cummins JE; Sanders-Beer BE
    Antimicrob Agents Chemother; 2008 May; 52(5):1768-81. PubMed ID: 18316528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Candidate polyanion microbicides inhibit HIV-1 infection and dissemination pathways in human cervical explants.
    Fletcher PS; Wallace GS; Mesquita PM; Shattock RJ
    Retrovirology; 2006 Aug; 3():46. PubMed ID: 16882346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
    Fletcher P; Harman S; Azijn H; Armanasco N; Manlow P; Perumal D; de Bethune MP; Nuttall J; Romano J; Shattock R
    Antimicrob Agents Chemother; 2009 Feb; 53(2):487-95. PubMed ID: 19029331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blocking of cell-free and cell-associated HIV-1 transmission through human cervix organ culture with UC781.
    Zussman A; Lara L; Lara HH; Bentwich Z; Borkow G
    AIDS; 2003 Mar; 17(5):653-61. PubMed ID: 12646787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MIV-150/zinc acetate gel inhibits cell-associated simian-human immunodeficiency virus reverse transcriptase infection in a macaque vaginal explant model.
    Barnable P; Calenda G; Bonnaire T; Menon R; Levendosky K; Gettie A; Blanchard J; Cooney ML; Fernández-Romero JA; Zydowsky TM; Teleshova N
    Antimicrob Agents Chemother; 2015 Jul; 59(7):3829-37. PubMed ID: 25870063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicide.
    Rohan LC; Moncla BJ; Kunjara Na Ayudhya RP; Cost M; Huang Y; Gai F; Billitto N; Lynam JD; Pryke K; Graebing P; Hopkins N; Rooney JF; Friend D; Dezzutti CS
    PLoS One; 2010 Feb; 5(2):e9310. PubMed ID: 20174579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of seminal plasma in the anti-HIV-1 activity of candidate microbicides.
    Neurath AR; Strick N; Li YY
    BMC Infect Dis; 2006 Oct; 6():150. PubMed ID: 17042959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A glycomimetic compound inhibits DC-SIGN-mediated HIV infection in cellular and cervical explant models.
    Berzi A; Reina JJ; Ottria R; Sutkeviciute I; Antonazzo P; Sanchez-Navarro M; Chabrol E; Biasin M; Trabattoni D; Cetin I; Rojo J; Fieschi F; Bernardi A; Clerici M
    AIDS; 2012 Jan; 26(2):127-37. PubMed ID: 22045343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical evaluation of synthetic -2 RANTES as a candidate vaginal microbicide to target CCR5.
    Kish-Catalone TM; Lu W; Gallo RC; DeVico AL
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1497-509. PubMed ID: 16569870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of candidate microbicides cellulose acetate 1,2-benzenedicarboxylate and UC781 has synergistic and complementary effects against human immunodeficiency virus type 1 infection.
    Liu S; Lu H; Neurath AR; Jiang S
    Antimicrob Agents Chemother; 2005 May; 49(5):1830-6. PubMed ID: 15855503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical safety assessments of UC781 anti-human immunodeficiency virus topical microbicide formulations.
    Patton DL; Sweeney YT; Balkus JE; Rohan LC; Moncla BJ; Parniak MA; Hillier SL
    Antimicrob Agents Chemother; 2007 May; 51(5):1608-15. PubMed ID: 17353240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mouse model of cervicovaginal toxicity and inflammation for preclinical evaluation of topical vaginal microbicides.
    Catalone BJ; Kish-Catalone TM; Budgeon LR; Neely EB; Ferguson M; Krebs FC; Howett MK; Labib M; Rando R; Wigdahl B
    Antimicrob Agents Chemother; 2004 May; 48(5):1837-47. PubMed ID: 15105142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A dual chamber model of female cervical mucosa for the study of HIV transmission and for the evaluation of candidate HIV microbicides.
    Van Herrewege Y; Michiels J; Waeytens A; De Boeck G; Salden E; Heyndrickx L; van den Mooter G; de Béthune MP; Andries K; Lewi P; Praet M; Vanham G
    Antiviral Res; 2007 May; 74(2):111-24. PubMed ID: 17097156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of frozen-thawed cervical tissues in the organ culture system to measure anti-HIV activities of candidate microbicides.
    Gupta P; Ratner D; Patterson BK; Kulka K; Rohan LC; Parniak MA; Isaacs CE; Hillier S
    AIDS Res Hum Retroviruses; 2006 May; 22(5):419-24. PubMed ID: 16706618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.